Recent Updates
Recently added Catalysts
AEMD Positive Sentiment

Aethlon Medical to Release Fiscal Second Quarter Financial Results and Host Conference Call on November 12, 2025

Friday, November 7, 2025 BiopharmaWatch Research 2 min read
Add on Google
Key Takeaway: Aethlon Medical, Inc. will release its fiscal second quarter financial results on November 12, 2025, at 4:15 p.m. ET. Following this, a conference call will be held at 4:30 p.m. ET to discuss the results and recent corporate developments. The Hemopurifier, an investigational device, aims to treat advanced cancer and life-threatening viral infections.
Price reaction · baseline $4.26 (2025-11-06 close) · hit pre-market · 1 other AEMD headline(s) in the window, move may be shared
day 0 close · peak
-1.6%

Market Sentiment Analysis

POSITIVE FACTORS

  • Aethlon Medical is advancing innovative therapies for cancer and infectious diseases.
  • The Hemopurifier has received Breakthrough Device Designation from the FDA.
  • The upcoming conference call will provide insights into financial results and corporate developments.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+35%
120-day peak, hindsight
Typical move
6.1%
average across 3 past catalysts
Cash runway
~7 mo
Medium dilution risk

Full Press Release Details

SAN DIEGO,Nov. 7, 2025/PRNewswire/ --Aethlon Medical, Inc.(Nasdaq:AEMD), a medical therapeutic company focused on developing products to treat cancer and life threatening infectious diseases, today announced that it will issue financial results for its fiscal second quarter ended September 30, 2025, at 4:15 p.m. ET on Wednesday, November 12, 2025.
Management will host a conference call on Wednesday, November 12, 2025, at 4:30 p.m. ET to review financial results and recent corporate developments. Following management's formal remarks, there will be a question and answer session.
Interested parties can register for the conference call by navigating tohttps://dpregister.com/sreg/10204579/1005d2109f4. Please note that registered participants will receive their dial-in number upon registration.
Interested parties without internet access or unable to pre-register may dial in by calling:
PARTICIPANT DIAL IN (TOLL FREE): 1-844-836-8741PARTICIPANT INTERNATIONAL DIAL IN: 1-412-317-5442
All callers should ask for the Aethlon Medical, Inc. conference call.
A replay of the call will be available approximately one hour after the end of the call through December 12, 2025. The replay can be accessed via Aethlon Medical's website or by dialing 1-855-669-9658 (domestic) or 1-412-317-0088 (international) or Canada toll free at 1-855-669-9658. The replay conference ID number is 1454680.
About the Hemopurifier®
The Aethlon Hemopurifier is an investigational medical device designed to remove enveloped viruses and tumor-derived extracellular vesicles (EVs) from circulation. It is used extracorporeally with a blood pump and combines plasma separation, size exclusion, and affinity binding using a plant lectin resin that targets mannose-rich surfaces found on EVs and viruses. EVs released by solid tumors are believed to play a role in metastasis and the resistance to immunotherapies and chemotherapy. Removal of enveloped viruses and extracellular vesicles has been demonstrated in both vitro studies and human subjects.
The Hemopurifier holds a U.S. Food and Drug Breakthrough Device Designation for:
The treatment of individuals with advanced or metastatic cancer unresponsive to or intolerant of standard-of-care therapy; and the treatment of life-threatening viruses not addressed with approved therapies.
About Aethlon Medical, Inc.
Aethlon Medical, Inc. (Nasdaq:AEMD) is a clinical-stage medical device company headquartered in San Diego, California. Aethlon is advancing the Hemopurifier, to address unmet needs in oncology and infectious disease, using a novel platform designed to selectively remove circulation pathogenic targets from biologic fluids.
For more information, visitwww.AethlonMedical.comand follow the company on LinkedIn.

Forward Looking StatementsThis press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 that involve risks and uncertainties. Statements containing words such as "may," "believe," "anticipate," "expect," "intend," "plan," "project," "will," "projections," "estimate," "potentially" or similar expressions constitute forward-looking statements. Such forward-looking statements are subject to significant risks and uncertainties and actual results may differ materially from the results anticipated in the forward-looking statements. These forward-looking statements are based upon Aethlon's current expectations and involve assumptions that may never materialize or may prove to be incorrect. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except as may be required by law, the Company does not intend, nor does it undertake any duty, to update this information to reflect future events or circumstances.

Company Contact:Jim FrakesChief Executive Officer and Chief Financial OfficerAethlon Medical, Inc.[email protected]

Investor Contact:Susan NoonanS.A. Noonan Communications, LLC[email protected]

Frequently Asked Questions

When will Aethlon Medical release its Q2 financial results?

Aethlon Medical will release its Q2 financial results on November 12, 2025, at 4:15 p.m. ET.

What is the purpose of the conference call?

The conference call will review financial results and recent corporate developments.

How can I participate in the conference call?

Participants can register online or dial in using the provided toll-free numbers.

What is the Hemopurifier?

The Hemopurifier is an investigational device designed to remove viruses and tumor-derived vesicles.

ShareAdd on Google
Tags: AEMD Viatris Investor Conferences Healthcare Aethlon Medical Hemopurifier financial results conference call
Last updated: Nov 7, 2025

Biotech snapshot

Cash runway
$5M liquidity · $1M/mo burn
~7 mo
Medium dilution risk

Catalyst track record

+35%
best trade around AEMD's most recent catalyst

Peak hindsight return over a 120-day window, across 3 tracked FDA/PDUFA catalysts for AEMD.

See every catalyst's timing & PoA →